Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00543400 · ClinicalTrials.gov registry record · Phase 2
Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)
A Phase 2 study, sponsored by Momenta Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 503
- Enrollment target
NCT00543400 is a Phase 2 study that has completed, run by Momenta Pharmaceuticals. The registered enrollment target is 503 participants.
The verdict
NCT00543400, a Phase 2 study, has completed, sponsored by Momenta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 503 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the safety and feasibility of using M118 as an anticoagulant in the target population of subjects with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). The secondary objectives are to evaluate the effect of M118 on procedural indices including procedure success, abrupt closure, post-procedure TIMI flow, and catheter thrombus. Substudy Primary Objective The primary objective of the substudy is to characterize the pharmacokinetic and pharmacodynamic profile of M118 among subjects with stable coronary artery disease undergoing elective PCI.
Interventions
- DRUG Unfractionated Heparin
- DRUG M118
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 503 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00543400
The ClinicalTrials.gov registry entry for NCT00543400 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 503 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Momenta Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Unfractionated Heparin is the first listed.
NCT00543400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00543400 about?
NCT00543400 is a clinical study titled "Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)". The primary objective is to evaluate the safety and feasibility of using M118 as an anticoagulant in the target population of subjects with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). The secondary objectives are to evaluate the effect of M118 on proced...
What is the current status of trial NCT00543400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 503 participants. The study started on 2007-09. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00543400?
The interventions under investigation include: Unfractionated Heparin (DRUG), M118 (DRUG).
Who is sponsoring clinical trial NCT00543400?
This trial is sponsored by Momenta Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.